Empagliflozin (Jardiance)
SGLT2 inhibitor · SGLT2 class · oral smd · Boehringer Ingelheim
Top dose
25 mg
HbA1c reduction
-0.78%
at week 24 · efficacy
AE discontinuation
5.0%
Status
approved
Pivotal trial
- Trial
- EMPA-REG (HbA1c)
- Indication
- type 2 diabetes
- Duration
- 24 weeks
- ClinicalTrials.gov
- NCT01131676
- Sponsor
- Boehringer Ingelheim
Notes
Modest HbA1c effect (~-0.7 to -0.8%) but the SGLT2 class leads on cardiovascular and renal outcomes (EMPA-REG OUTCOME, EMPEROR). Co-promoted by Lilly. Included for the durable cardio-renal story, not glycemic depth.